Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: Paul A who wrote (7192)	8/28/1999 2:48:00 PM
From: kendall harmon	Respond to of 7396

UTHR--Another one which could still go higher next week is UTHR, depending on the outcome of the paper to be delivered in Barcelona this coming Tuesday morning European time. The company is going to have an accompanying press release Tuesday evening U.S. time (confirmed to me through communications with IR). The market for their lead drug, UT-15, is very large, consider just one fact: The prevalence of x-ray measured pulmonary arteries with abnormally large diameters -- an indication of pulmonary hypertension -- is 13% of men over age 34. This means there may be tens of millions of people worldwide with pulmonary hypertension. The prevalence of people with diagnosed Primary Pulmonary Hypertension (PPH) is about ten persons per million. The number of diagnosed case of secondary pulmonary hypertension is approximately 50,000 persons in the U.S.and Europe.

To: Paul A who wrote (7192)	8/28/1999 3:16:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 7396

UTHR--a profile of the presenter of the key paper this Tuesday. For those who know the field it IS a big deal that he is the one presenting. Stuart Rich, M.D. is a Professor of Medicine and Director of the Center for Pulmonary Heart Disease in the Rush Heart Institute. He received his M.D. from Loyola University, completed his Internal Medicine Residency at Washington University in St. Louis, and his Cardiology Fellowship at the University of Chicago. Before coming to Rush in 1996, Dr. Rich was on the faculty and, since 1989, the Chief of the Section of Cardiology at the University of Illinois. Dr. Rich has established himself as a leading investigator in the area of pulmonary hypertension and pulmonary heart disease. He has been instrumental in the development of studies describing the natural history, pathophysiology, and treatment of all types of pulmonary hypertension and the development of prostacyclin as a recently FDA approved treatment. source:http://www.rush.edu/Departments/PulmonaryHeart/Physicians/about.html